Literature DB >> 15876935

Pertussis immunization in the global pertussis initiative international region: recommended strategies and implementation considerations.

Kevin Forsyth1, Masaaki Nagai, Alejandro Lepetic, Evelinda Trindade.   

Abstract

Despite widespread immunization programs in most countries, pertussis disease continues to be a threat to public health. In particular, there has been a resurgence of pertussis disease in older children, adolescents and adults, creating a reservoir of infection, which poses a significant threat to infants who are either unimmunized or incompletely immunized. Global Pertussis Initiative participants from Argentina, Australia, Brazil and Japan considered the relative merits of several strategies to reduce the burden of pertussis disease and suggested strategies that might be implemented in these countries. Infants in these countries receive an initial course of 3 doses of vaccine in the first year of life followed by a fourth dose in the second year. Only children in Japan are not given a preschool booster (age 3-5 years). Of the strategies considered, the addition of a preschool booster is therefore a priority in Japan to overcome the problem of waning vaccine-induced immunity to pertussis in school children. Waning immunity also affects adolescents; Australia introduced an adolescent booster in 2003, and the addition of a booster in this age group was suggested for Argentina and Japan. Immunization of new mothers and other close contacts of young infants, such as child care and health care workers, might be appropriate in Australia in the future. Argentina also suggested a future possibility of immunizing health care and child care workers. Obstacles to new immunization strategies include poor access to standardized laboratory diagnostic techniques, inadequate resources to fund new immunization programs, low awareness of pertussis disease in adults and adolescents and inadequate surveillance techniques to assess the full extent of the problems caused by pertussis or the impact new vaccination strategies might have.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15876935     DOI: 10.1097/01.inf.0000160921.74004.12

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  13 in total

1.  Proficiency program for real-time PCR diagnosis of Bordetella pertussis infections in French hospital laboratories and at the French National Reference Center for Whooping Cough and other Bordetelloses.

Authors:  Valérie Caro; Nicole Guiso; Corinne Alberti; Sandrine Liguori; Christophe Burucoa; Gérard Couetdic; Florence Doucet-Populaire; Agnès Ferroni; Sophie Papin-Gibaud; Florence Grattard; Hélène Réglier-Poupet; Josette Raymond; Catherine Soler; Sylvie Bouchet; Sandrine Charreau; Brigitte Couzon; Isabelle Leymarie; Nicole Tavares; Mathilde Choux; Edouard Bingen; Stéphane Bonacorsi
Journal:  J Clin Microbiol       Date:  2009-08-19       Impact factor: 5.948

2.  Is the Sequenced Bordetella pertussis strain Tohama I representative of the species?

Authors:  Valérie Caro; Valérie Bouchez; Nicole Guiso
Journal:  J Clin Microbiol       Date:  2008-04-02       Impact factor: 5.948

3.  Development and analytical validation of an immunoassay for quantifying serum anti-pertussis toxin antibodies resulting from Bordetella pertussis infection.

Authors:  Sandra L Menzies; Vijay Kadwad; Lucia C Pawloski; Tsai-Lien Lin; Andrew L Baughman; Monte Martin; Maria Lucia C Tondella; Bruce D Meade
Journal:  Clin Vaccine Immunol       Date:  2009-10-28

4.  Attitude toward immunization and risk perception of measles, rubella, mumps, varicella, and pertussis in health care workers working in 6 hospitals of Florence, Italy 2011.

Authors:  Cristina Taddei; Vega Ceccherini; Giuditta Niccolai; Barbara Rita Porchia; Sara Boccalini; Miriam Levi; Emilia Tiscione; Maria Grazia Santini; Simonetta Baretti; Paolo Bonanni; Angela Bechini
Journal:  Hum Vaccin Immunother       Date:  2014-10-30       Impact factor: 3.452

5.  Immunogenicity and reactogenicity of two diphtheria-tetanus-whole cell pertussis vaccines in Iranian pre-school children, a randomized controlled trial.

Authors:  Saeed Zarei; Mahmood Jeddi-Tehrani; Mohammad Mehdi Akhondi; Hojjat Zeraati; Amir Ali Ferydonfar; Jalaledin Nasernia; Banafsheh Tavangar; Fazel Shokri
Journal:  Hum Vaccin Immunother       Date:  2013-02-26       Impact factor: 3.452

6.  Pertussis knowledge, attitude and practices among European health care professionals in charge of adult vaccination.

Authors:  Muriel Hoffait; David Hanlon; Bernd Benninghoff; Stijn Calcoen
Journal:  Hum Vaccin       Date:  2011-02-01

7.  Management of vaccine safety in Korea.

Authors:  Young June Choe; Geun-Ryang Bae
Journal:  Clin Exp Vaccine Res       Date:  2013-01-15

8.  Modelling pertussis transmission to evaluate the effectiveness of an adolescent booster in Argentina.

Authors:  G Fabricius; P E Bergero; M E Ormazabal; A L Maltz; D F Hozbor
Journal:  Epidemiol Infect       Date:  2012-07-06       Impact factor: 4.434

9.  Perspectives on vaccine injury compensation program in Korea: the pediatricians' view.

Authors:  Dae Sun Jo; Jung Soo Kim
Journal:  Clin Exp Vaccine Res       Date:  2013-01-15

10.  Analysis of Bordetella pertussis pertactin and pertussis toxin types from Queensland, Australia, 1999-2003.

Authors:  Shane Byrne; Andrew T Slack
Journal:  BMC Infect Dis       Date:  2006-03-16       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.